{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:07:39Z","timestamp":1791338859960,"version":"4.3.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.breast.2026.104778","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:11:25Z","timestamp":1775135485000},"page":"104778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["International comparisons of survival after recurrent metastatic breast cancer in four countries: A population-based study"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6976-819X","authenticated-orcid":false,"given":"Hanna","family":"Fink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Soerjomataram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Bardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan R.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lou","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan F.","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serban","family":"Negoita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"Ramirez-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gelmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gralow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104778_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104778_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104778_bib3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104778_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13058-024-01881-y","article-title":"Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis","volume":"26","author":"Morgan","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104778_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","article-title":"Extending survival with chemotherapy in metastatic breast cancer","volume":"10","author":"O'Shaughnessy","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104778_bib6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41416-022-01845-z","article-title":"Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study","volume":"127","author":"Valachis","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071255","article-title":"Metastatic breast cancer: prolonging life in routine oncology care","volume":"16","author":"Weide","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104778_bib8","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00432-020-03184-z","article-title":"Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center","volume":"146","author":"Welt","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104601","article-title":"Knowledge in motion: a decade reviewed, a future defined - the ABC global alliance 2015-2025 decade report and 2025-2035 global charter","volume":"84","author":"Cardoso","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104778_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104778_bib11","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104778_bib13","article-title":"Systemic treatment of patients with metastatic breast cancer: ASCO resource\u2013stratified guideline","author":"Sukhun","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-017-4210-z","article-title":"Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach","volume":"164","author":"Andreano","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104778_bib15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.6004\/jnccn.2018.7001","article-title":"Adherence to guidelines for breast surveillance in breast cancer survivors","volume":"16","author":"Ruddy","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.breast.2026.104778_bib16","article-title":"Collecting long-term outcomes in population-based cancer registry data: the case of breast cancer recurrence","volume":"10","author":"Morgan","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: an overview of measures, uses, and interpretation","volume":"2014","author":"Mariotto","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.breast.2026.104778_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101802","article-title":"The world cancer patient population (WCPP): an updated standard for international comparisons of population-based survival","volume":"69","author":"Miranda-Filho","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.breast.2026.104778_bib19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ijc.27725","article-title":"Breast cancer survival in the US and Europe: a CONCORD high-resolution study","volume":"132","author":"Allemani","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/bjc.2013.6","article-title":"Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study","volume":"108","author":"Walters","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib22","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1245\/s10434-021-10227-3","article-title":"Survival outcomes among patients with metastatic breast cancer: review of 47,000 patients","volume":"28","author":"Taskindoust","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026414","article-title":"Metastatic breast cancer incidence, site and survival in Australia, 2001-2016: a population-based health record linkage study protocol","volume":"9","author":"Lord","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2026.104778_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/curroncol29010034","article-title":"Survival in Women with De Novo Metastatic Breast Cancer: a Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status","volume":"29","author":"Savard","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib25","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/cncr.27819","article-title":"Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years","volume":"119","author":"Tevaarwerk","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12885-018-4158-3","article-title":"Burden of early, advanced and metastatic breast cancer in the Netherlands","volume":"18","author":"Vondeling","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12282-009-0103-2","article-title":"Disparities in the survival improvement of recurrent breast cancer","volume":"17","author":"Anan","year":"2010","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10549-018-4936-2","article-title":"Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry","volume":"172","author":"Falato","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104778_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038798","article-title":"Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital","volume":"10","author":"Karihtala","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2026.104778_bib30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s12282-018-0869-1","article-title":"Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study","volume":"25","author":"Lee","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.breast.2015.06.003","article-title":"Survival time according to the year of recurrence and subtype in recurrent breast cancer","volume":"24","author":"Nakano","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104778_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10549-011-1372-y","article-title":"Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry","volume":"128","author":"van den Hurk","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104778_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102370","article-title":"Breast and colorectal cancer recurrence-free survival estimates in the US: modeling versus active data collection","volume":"85","author":"Mariotto","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.breast.2026.104778_bib34","first-page":"173","article-title":"The challenges of collecting long-term outcomes in cancer patients on the population-level: the case of metastatic breast cancer","volume":"50","author":"Morgan","year":"2023","journal-title":"J Registry Manag"},{"key":"10.1016\/j.breast.2026.104778_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv134","article-title":"Challenges and opportunities in measuring cancer recurrence in the United States","volume":"107","author":"Warren","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104778_bib37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fonc.2019.00510","article-title":"Endocrine and targeted therapy for hormone-receptor-positive, HER2-Negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials","volume":"9","author":"El","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100567","article-title":"Capturing breast cancer subtypes in cancer registries: insights into real-world incidence and survival","volume":"44","author":"Vaz-Gon\u00e7alves","year":"2025","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.breast.2026.104778_bib39","article-title":"Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada","volume":"26","author":"Gambaro","year":"2023","journal-title":"J Pharm Pharmaceut Sci"},{"key":"10.1016\/j.breast.2026.104778_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and future management of HER2-Positive metastatic breast cancer","volume":"17","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.breast.2026.104778_bib41","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1078-0432.CCR-21-2600","article-title":"U.S. FDA drug approvals for breast cancer: a decade in review","volume":"28","author":"Arora","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2026.104778_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10549-007-9699-0","article-title":"The early days of letrozole","volume":"105","author":"Bhatnagar","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104778_bib43","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1340764","article-title":"Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy","volume":"15","author":"Cao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.breast.2026.104778_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s12282-020-01054-7","article-title":"First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis","volume":"27","author":"Shimoi","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104778_bib46","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1158\/1078-0432.CCR-13-1212","article-title":"First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer","volume":"19","author":"Blumenthal","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104778_bib47","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-Negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104778_bib48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/1758834014539183","article-title":"Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential","volume":"6","author":"Peddi","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.56170","article-title":"Regulatory approval, reimbursement, and clinical use of cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer in the Netherlands","volume":"6","author":"Luyendijk","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2026.104778_bib51","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.2013-0348","article-title":"The European medicines agency review of pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use","volume":"19","author":"Boix-Perales","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104778_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100074","article-title":"The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer","volume":"6","author":"Delgado","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104778_bib53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jamaoncol.2021.8049","article-title":"Cost-effectiveness analysis of pertuzumab with trastuzumab in patients with metastatic breast cancer","volume":"8","author":"Dai","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib54","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.3390\/curroncol29120778","article-title":"Access to neoadjuvant pertuzumab for HER2 positive breast cancer in Canada: a dilemma increasingly difficult to explain","volume":"29","author":"Rayson","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-022-06832-9","article-title":"Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry","volume":"198","author":"Ibragimova","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104778_bib56","series-title":"Pertuzumab: reimbursement recommendation","year":"2025"},{"key":"10.1016\/j.breast.2026.104778_bib57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3747\/co.24.3648","article-title":"Impact of the pan-canadian oncology drug review on provincial concordance with respect to cancer drug funding decisions and time to funding","volume":"24","author":"Srikanthan","year":"2017","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2026.104778_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120832","article-title":"Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval","volume":"10","author":"Witteveen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2026.104778_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:57:48Z","timestamp":1778925468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":58,"alternative-id":["S0960977626000883"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104778","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International comparisons of survival after recurrent metastatic breast cancer in four countries: A population-based study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104778"}}